Difference between revisions of "Tropisetron (Navoban)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== [http://www.cancer.gov/drugdictionary?CdrID=43507 From NCI]: "An indole derivative with antiemetic activity. As a selective serotonin receptor antagoni...") |
Warner-admin (talk | contribs) m (Text replacement - "5HT3" to "5-HT3") |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | [http://www.cancer.gov/drugdictionary?CdrID=43507 From NCI]: "An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at | + | [http://www.cancer.gov/drugdictionary?CdrID=43507 From NCI]: "An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting." |
==History of FDA approval== | ==History of FDA approval== | ||
Revision as of 03:24, 18 November 2017
Mechanism of action
From NCI: "An indole derivative with antiemetic activity. As a selective serotonin receptor antagonist, tropisetron competitively blocks the action of serotonin at 5-HT3 receptors, resulting in suppression of chemotherapy-and radiotherapy-induced nausea and vomiting."
History of FDA approval
Not FDA-approved; available in several countries
Also known as
ICS 205-930, Setrovel